3 New Strong Buy Ratings from Top-Rated Analysts: 09/22/2026
Here’s what Wall Street’s brightest and best are watching today:
- CVS Health (CVS): Sixteen analysts bullish, upside targets 40%+
- Riskified (RSKD): #1 in its industry with excellent growth prospects
- Avient (AVNT): Analysts see significant upside ahead
P.S. Get more alerts like this daily … Try WallStreetZen Premium.
A note from our sponsors...
The ONLY AI opportunity you should be looking at
This is the ONLY AI wealth-building opportunity you should be watching right now.
No. It's not about Nvidia, Tesla, or Meta...
It's about one overlooked company profiting off AI "digital goldmines" that are poised to experience 100x growth very soon.
This new opportunity will change the market and make investors a lot of money.
That's why it has received a $500 billion commitment from President Trump himself...
Learn more about this little-known company here >>>
1. Riskified (NYSE: RSKD)
This e-commerce risk management company is capitalizing on the surge in complex fraud patterns driving merchant demand for its unified platform, which delivered its strongest revenue growth in over four years.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $6.21 — get current quote
Max 1-year forecast: $7.50
Why we're watching:
- RSKD has limited, but overall bullish, coverage among the analysts we track, with 1 Strong Buy and 2 Hold recommendations. See all recommendations here
- For example, DA Davidson researcher Clark Wright (a top 17% rated analyst) recently maintained his Strong Buy rating with a price target suggesting the stock could see greater than 20% upside in the coming year.
- Perhaps more telling, it was recently chosen as our Editor-in-Chief’s Stock of the Week, where Steve Reitmeister calls it one of the best “low-priced tech stocks with high upside potential.” See his full commentary here.
- Q2 earnings demonstrated execution strength: EPS of $0.02 missed estimates by 3.33% with 0% year-over-year growth, while revenue of $98.69M exceeded expectations by 12.15% with 22% YoY growth.
- Industry ranking context: RSKD is currently the #1 highest-rated stock in the App industry, which has an Industry Rating of B.
- Zen Ratings highlights: RSKD earns an overall A rating, which amounts to a Strong Buy recommendation. Stocks in this topmost tier have historically delivered nearly 30% annual returns, soundly beating the S&P.
- Component Grades: RSKD shines with an A for Growth, reflecting accelerating revenue momentum and merchant adoption of its fraud prevention platform, while maintaining solid Bs for Financials, Momentum, and Sentiment, positioning it for continued expansion in the e-commerce security space. See all 7 Component Grades here
2. Avient (NYSE: AVNT)
Avient manufactures specialized polymer materials including thermoplastic compounds, plastic colorants and additives, thermoplastic resins, and vinyl resins. The company is driving growth through broad-based revenue expansion and margin improvement across segments, with analysts highlighting productivity, mix, and pricing initiatives as catalysts for further valuation upside.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $40.36 — get current quote
Max 1-year forecast: $50.00
Why we're watching:
- AVNT has limited, but overall bullish, coverage among the analysts we track, with 2 Strong Buy recommendations. See all recommendations here
- For example, Truist Securities researcher Peter Osterland (a top 26% rated analyst) recently maintained his Strong Buy rating with a price target suggesting the stock could see greater than 20% upside in the coming year.
- Industry ranking context: AVNT is currently the #5 highest-rated stock in the Specialty Chemical industry, which has an Industry Rating of A.
- Zen Ratings highlights: AVNT earns an overall A rating, which amounts to a Strong Buy recommendation. Stocks with this rating represent the elite top 5% of all 4,600+ stocks tracked based on a rigorous 115-factor fundamental review.
- Component Grades: AVNT maintains strong Bs for Growth, Momentum, Safety, and Value, reflecting a well-balanced profile with solid fundamentals, positive business momentum, and attractive valuation metrics that position the specialty polymer maker for continued appreciation. See all 7 Component Grades here
3. CVS Health (NYSE: CVS)
It’s not just the drugstores! This company also encompasses Aetna health insurance, among other brands. They’re streamlining cancer treatment approvals through Aetna and expanding its consumer wellness initiatives while analysts see significant upside ahead of an anticipated strong earnings ramp-up.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $88.84 — get current quote
Max 1-year forecast: $125.00
Why we're watching:
- CVS has strong, bullish coverage among the analysts we track, with 11 Strong Buy and 5 Buy recommendations. See all recommendations here
- For example, UBS researcher Kevin Caliendo (a top 15% rated analyst) recently maintained his Strong Buy rating with a $118.00 price target, representing 32.82% upside potential from current levels.
- Likewise, Evercore ISI Group researcher Elizabeth Anderson (a top 17% rated analyst) maintained her Buy with a price target suggesting the stock could see greater than 40% upside in the coming year.
- Industry ranking context: CVS is currently the #3 highest-rated stock in the Healthcare Plan industry, which has an Industry Rating of A.
- Zen Ratings highlights: CVS earns an overall A rating, which is equal to a Strong Buy recommendation. This tier represents the elite top 5% of all 4,600+ stocks tracked based on a rigorous 115-factor fundamental review.
- Component Grades: CVS excels for Sentiment with an A grade, reflecting Wall Street's bullish conviction and the market's recognition of its strategic positioning across pharmacy, benefits management, and insurance, while maintaining solid Bs for Growth and Safety, a combination that suggests resilience and expansion potential. See all 7 Component Grades here
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.
Keep Reading
See All News
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.